Oncogenic mutations in KRAS are detectable in nearly one‐quarter of a wide variety of cancers, predominantly in PDAC (86–90%), colorectal cancer (41%), and NSCLC (32%).[34, 35] Due to a lack of pharmacologically targetable pockets within the mutant isoforms, KRAS has historically been considered ‘undruggable’. This evidence concerns the gene KRAS and cancer.